Skip to content
PPepIndex

Humanin

Other

Also known as HN, MTRNR2

2.5/ 5evidence coverage 52%
B

Evidence tier

Substantial published literature

495 publications over 56 years · trials not yet curated

Researched since
1970
Publications
495
Mean purity
Vendors listing
1

No indexed vendor publishes certificate records for Humanin that this index could read yet, so no purity comparison is possible.

Score breakdown

The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.

Research evidence24.0 / 24

Studied since 1970 — 56 years of published research

How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.

Research volume14.0 / 14

495 publications indexed in PubMed

The volume of published literature located. Full marks at fifty or more publications.

Vendor purity0.0 / 22

No certificate records indexed yet — nothing recorded yet

Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.

Lot-to-lot consistency0.0 / 12

No certificate records indexed yet — nothing recorded yet

How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.

Testing transparency12.3 / 14

1 of 1 listing vendor publish an accessible certificate policy

Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.

Third-party testing0.0 / 14

No certificate records indexed yet — nothing recorded yet

Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.

Total50.3 / 100

What is Humanin?

A mitochondrial-derived peptide studied for cytoprotective and neuroprotective effects in models of ageing and metabolism.

Studied in published research for neuroprotection, metabolism and ageing.

Regulatory status

Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.

What the research examines

1 area

The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.

Published research

8 citations

Published work is largely preclinical, in cell and animal models. PepIndex does not evaluate clinical significance and does not describe administration.

PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.

Vendor comparison

Vendors are ranked for Humaninspecifically: the score folds in this compound’s price per milligram against the market median, alongside the same documentation and testing that drive the overall board — so a vendor that is cheap on Humanin outranks a pricier one of equal documentation, even if the pricier vendor sits higher overall. A vendor without a captured price for Humanin is judged on its overall basket price. Purity and deviation come from the certificate records indexed for each vendor.
VendorScore herePrice / mgCertificatesMean purityLabel deviationGet it
American PeptidesISO/IEC 1702586.5100%$15.00 (100%)0

Certificate records

0 lot records

No certificate records are indexed. Either none are published, or those published could not be read without an account.

How to read a certificate of analysis